Pfizer, BioNTech say vaccine is 95% effective, EUA submission 'within days'

Jason Mast

Editor

Pfizer and BioNTech have done the final efficacy analysis for their Phase III Covid-19 trial, and the results confirm the headline-grabbing release from last …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Pfizer, BioNTech say vaccine is 95% effective, EUA submission 'within days'

Jason Mast

Editor

Sign up to read this article for free.

Trump names Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, Surgeon General picks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

Patient dies in Neurogene's Rett syndrome study

Are programs with compounded GLP-1s safe for your population?

Pfiz­er, BioN­Tech say vac­cine is 95% ef­fec­tive, EUA sub­mis­sion 'with­in days'

Jason Mast

Editor

Sign up to read this article for free.

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

Pfizer, BioNTech say vaccine is 95% effective, EUA submission 'within days'

Trump names Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, Surgeon General picks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

Patient dies in Neurogene's Rett syndrome study

Are programs with compounded GLP-1s safe for your population?